default author photo

Shani Paluch-Shimon

Hebrew University of Jerusalem - The Sharett Institute of Oncology

Jerusalem

Israel

SCHOLARLY PAPERS

1

DOWNLOADS

52

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Adjuvant Ovarian Function Suppression and Aromatase Inhibitors in Premenopausal Patients with Hormone Receptor And Her2 Positive Breast Cancer, by Timing of Chemotherapy and Trastuzumab and Response to Neoadjuvant Therapy

Number of pages: 22 Posted: 16 Jul 2025
Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - University Hospitals Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, affiliation not provided to SSRN, University of Gothenburg - Sahlgrenska University Hospital, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), affiliation not provided to SSRN, affiliation not provided to SSRN, Université de Lille - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Institute of Oncology, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Santa Maria Local Health Unit, affiliation not provided to SSRN, affiliation not provided to SSRN, HFR Fribourg Cantonal Hospital, Bank of Cyprus Oncology Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Istinye University, Maastricht University, AZ Turnhout, AZ Groeninge, Hebrew University of Jerusalem - Shaare Zedek Medical Center, affiliation not provided to SSRN, Hebrew University of Jerusalem - The Sharett Institute of Oncology, IRCCS Ospedale Policlinico San Martino, Technion-Israel Institute of Technology - Rambam Health Care Campus, KU Leuven - Department of Gynecologic Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Technion-Israel Institute of Technology - Rambam Health Care Campus, affiliation not provided to SSRN, Istinye University, European Commission, Joint Research Centre and Netherlands Cancer Institute
Downloads 52 (1,041,696)

Abstract:

Loading...

Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response